Lilly names new head of cancer drug business
Eli Lilly and Co. on Friday named company insider Sue Mahony as president of its cancer drug business.
Health Care
Articles
Lilly takeover provision to be voted on again
The effort to remove an 80-percent approval threshold for takeover bids against the wishes of Lilly’s board is on the agenda of the company’s April 18 annual meeting.
Medicaid expansion could tax community health centers
The president of the Indiana Primary Health Care Association wants to double the number of federally qualified community health centers in Indiana in the next five years.
Repeated price cuts take glow off Endocyte IPO
New investors got in for $6 a share—which is less than the average price paid by prior investors, a regulatory filing reveals.
Health insurers expect hit from reform rule
Major health insurers, including WellPoint, say a provision that requires them to spend a certain percentage of the premiums they collect on care-related costs will eat into earnings this year.
Arcadia reports smaller loss on increased revenue
The Indianapolis-based health care company lost $2.3 million on revenue of $26.2 million in its third fiscal quarter.
Lilly collaboration with outside researchers yields first deal
Eli Lilly and Co.’s PD2 project attracted 30,000 compounds from researchers in 26 countries. And Lilly scientist Alan Palkowitz said it’s just the first of many such collaborations.
Eli Lilly CEO Lechleiter sees 2010 pay fall 22 percent
Eli Lilly and Co. Chairman and CEO John Lechleiter received compensation valued at $12.7 million last year, down 22 percent from 2009 largely due to a change in how the drugmaker handles equity awards.
2010 compensation fell about 20 percent for top Lilly execs
Compensation for Eli Lilly and Co.’s top executives fell last year due to a change to its stock award program and as the company struggled to bring new medicines to market.
Panel OKs criminal checks on medical workers
Physicians, dentists, nurses, veterinarians, pharmacists and other medical workers would have to pay for a national criminal background check when applying for a state license under a bill pending with the Indiana Senate.
Potential competitor to Lilly drug shows promise in study
Sanofi-Aventis’s experimental diabetes drug lixisenatide, given to volunteer patients once a day, was at least as effective as Eli Lilly and Co. and Amylin Pharmaceuticals Inc.’s twice-daily medicine Byetta, a study found.
Judge’s ruling raises uncertainty for health care execs
After a federal judge in Florida struck down the entire health reform law, investors shrugged. But the uncertainty for executives in health care companies increased.
Florida judge strikes down health care overhaul
A federal judge ruled Monday that the Obama administration's health care overhaul is unconstitutional, siding with 26 states, including Indiana, that sued to block it.
Execs from WellPoint, peers meet to hone health-law lobby
Top executives from WellPoint Inc. and UnitedHealth Group Inc. are meeting almost monthly with their counterparts from Aetna Inc., Cigna Corp. and Humana Inc. in an informal lobbying alliance aimed at blunting parts of the health-care law, say sources with knowledge of the sessions.
King Systems’ two top execs exit company
An executive at the Noblesville firm’s parent company said the departures of CEO Don Dumoulin and Chief Financial Officer Yun Kim were the result of a “mutual agreement.” A search is under way for replacements to lead one of the area’s largest medical device manufacturers.
Indiana Health Information Exchange hires new CEO
Harold Apple takes over for J. Marc Overhage, who will remain with the organization as its chief strategic officer and national policy adviser. IHIE is one of four operational exchanges in Indiana that allows for the sharing of medical records electronically.
Lilly’s fourth-quarter profit surges, topping analysts’ predictions
The Indianapolis-based drugmaker earned $1.2 billion in the quarter, compared with $915 million in the same period a year ago. Profit per share beat Wall Street forecasts by a penny.
WellPoint profit better than analyst estimates
Excluding special charges, WellPoint’s profit fell 2 percent to $524.7 million in the fourth quarter from $536 million in the fourth quarter of 2009. But earnings per share improved thanks to stock buybacks.
Head of Lilly’s oncology unit resigning
John H. Johnson has been hired as CEO by East Brunswick, N.J.-based biotechnology company Savient Pharmaceuticals Inc.
Vanderbilt rejected by high court on Cialis patents
Supreme Court justices on Monday left intact a ruling throwing out a lawsuit pressed by the Nashville, Tenn., university against Eli Lilly’s Icos subsidiary.